Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple
doses of intramuscular INGAP Peptide given for the first time in humans as a potential
treatment for diabetes.